EKSO EKSO BIONICS HOLDINGS, INC.

Nasdaq eksobionics.com


$ 4.91 $ -0.11 (-2.24 %)    

Tuesday, 28-Oct-2025 19:41:03 EDT
QQQ $ 633.55 $ 4.83 (0.77 %)
DIA $ 476.83 $ 1.80 (0.38 %)
SPY $ 687.33 $ 1.82 (0.27 %)
TLT $ 92.10 $ 0.24 (0.26 %)
GLD $ 364.95 $ -2.63 (-0.72 %)
$ 4.81
$ 4.85
$ 4.52 x 800
$ 4.92 x 200
$ 4.61 - $ 4.99
$ 2.73 - $ 15.45
60,705
na
12.62M
$ 1.30
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-28-2025 09-30-2025 10-Q
2 07-28-2025 06-30-2025 10-Q
3 05-05-2025 03-31-2025 10-Q
4 03-03-2025 01-01-1970 10-K
5 10-28-2024 09-30-2024 10-Q
6 07-29-2024 06-30-2024 10-Q
7 04-29-2024 03-31-2024 10-Q
8 03-04-2024 12-31-2023 10-K
9 10-26-2023 09-30-2023 10-Q
10 07-27-2023 06-30-2023 10-Q
11 04-27-2023 03-31-2023 10-Q
12 03-28-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 07-28-2022 06-30-2022 10-Q
15 04-28-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 11-02-2021 09-30-2021 10-Q
18 07-29-2021 06-30-2021 10-Q
19 04-29-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 10-29-2020 09-30-2020 10-Q
22 07-31-2020 06-30-2020 10-Q
23 04-30-2020 03-31-2020 10-Q
24 02-27-2020 12-31-2019 10-K
25 10-30-2019 09-30-2019 10-Q
26 08-01-2019 06-30-2019 10-Q
27 05-01-2019 03-31-2019 10-Q
28 02-28-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-07-2018 06-30-2018 10-Q
31 05-07-2018 03-31-2018 10-Q
32 03-13-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-07-2017 06-30-2017 10-Q
35 05-09-2017 03-31-2017 10-Q
36 03-15-2017 12-31-2016 10-K
37 11-09-2016 09-30-2016 10-Q
38 08-03-2016 06-30-2016 10-Q
39 05-10-2016 03-31-2016 10-Q
40 03-14-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ekso-bionics-says-is-in-process-of-exploring-one-or-more-strategic-transactions-with-certain-third-parties-transactions-may-include-acquisition-of-line-of-business-andor-sale-of-all-or-substantially-all-of-cos-current-business

Exploration of Strategic TransactionsThe Company also announced today that it is in the process of exploring one or more strate...

 ekso-bionics-holdings-q3-eps-054-beats-115-estimate-sales-4227m-miss-4346m-estimate

Ekso Bionics Holdings (NASDAQ:EKSO) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of...

 ekso-bionics-secures-2m-term-loan-from-b-riley-at-10-interest-matures-september-14-2026

On September 12, 2025, Ekso Bionics Holdings, Inc. (the "Company") entered into a Secured Promissory Note and Security ...

 lake-street-maintains-buy-on-ekso-bionics-holdings-lowers-price-target-to-95

Lake Street analyst Ben Haynor maintains Ekso Bionics Holdings (NASDAQ:EKSO) with a Buy and lowers the price target from $15...

 ekso-bionics-holdings-q2-eps-124-beats-135-estimate-sales-2100m-miss-4313m-estimate

Ekso Bionics Holdings (NASDAQ:EKSO) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of...

 ekso-bionics-posts-on-x-announcing-ekso-bionics-new-ai-voice-agent--ekso-voice-agent

https://x.com/EksoBionics/status/1935374449596891611

 ekso-bionics-reschedules-1-for-15-reverse-stock-split-to-june-2-2025

Ekso Bionics Holdings, Inc. (the "Company") (NASDAQ:EKSO), a leading developer of exoskeletons for medical and industri...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION